T he receptive visual system is a multilayered convergent processing mechanism, beginning with retinal photoreceptors and ending in the occipital cortex. When the photoreceptors no longer work, such as in retinitis pigmentosa, blindness ensues. The downstream system in these patients is still intact, as evidenced by the vision created by non-specific electrical stimulation of their retinas by implanted photocells, which has resulted in formed vision allowing for finger counting. This shows the resilience and plasticity of our visual system to form images from this type of post-photoreceptor stimulation. Therefore, the question arises: is there a way to photo-activate the intact downstream retinal elements, such as bipolar and ganglion cells, in a more specific manner that would integrate the remaining retinal processing (such as on and off receptive fields or lateral inhibition) and yield significant improvement in vision? The answer is yes. Enter optogenetics.
Opsins are proteins that use the energy received by an attached chromophore to transform its configuration. This conformational change initiates various biological processes, including vision. Light-sensitive opsins are not only found in eyes but are also found elsewhere in living things, including in single-cell organisms such as algae (Figure 1) . In these simple plants, opsins are part of membrane-bound proteins that, upon stimulation with light, change the polarization across the cell membrane, allowing them to extract information and energy from the environment. These opsin complexes include systems that hyperpolarize or depolarize membranes with mechanisms that use captured light energy to drive chloride pumps, proton pumps, and channel-gates. Transferring these systems by genetic manipulation into the membranes of neural tissue, thereby making light a trigger of the neuron, is the field of optogenetics.
Optogenetics can restore vision by making the retina, downstream of the degenerated photoreceptors, light-sensitive. To do this, a gene that encodes a light-sensitive opsin trigger-system is incorporated into an adeno-associated virus vector (AAV), along with promoter sequences that specify the target retinal cells. The virus is then transfected into the target retinal cells, resulting in the incorporation of the gene into their genome. The expression of the gene product in the membranes of these retinal elements allows for light activation of the retina. The principle is easy, the devil is in the details.
The further upstream in the retina that the optogenetic sensitivity is created, the better the vision should be. Promoters that specifically target ON bipolar cells are currently being employed. Promoters to specifically target OFF bipolar cells have not been delineated as of yet. By modifying the capsid of the AAV, viral penetration of the retina to the bipolar cell layer is being achieved with intravitreal injections, obviating the need for intraretinal injection. Both microorganism-derived and vertebratederived rhodopsin-based optogenetic systems have been incorporated into the ON bipolar cells of blind mice whose photoreceptors were genetically knocked out. Each of these systems has its pros and cons.
Systems that employ rhodopsins from microorganisms use simple all-in-one light-sensitive membrane apparatuses, which hyperpolarize or depolarize the cell and do not require outside adjuncts. The signal output follows photic stimulation very rapidly with a fast recycle kinetic. Major problems with this system include the very high threshold of light needed to stimulate the cell and the very narrow wavelength range that produces excitation. Unless an object has a fair amount of blue light within its spectrum, it is not visualized. Engineering these systems to increase expression of the membrane components would lower the excitation light threshold. Manipulation of opsin systems to broaden wavelength response is currently in progress. External goggles that retransmit a more usable light to the bipolar cells are being investigated.
Vertebrate rhodopsins couple light-initiated excitation to a G protein receptor system (GPRS) that amplifies the initial signal. When vertebrate rhodopsin was optogenetically incorporated into the ON bipolar cells of genetically engineered blind mice, it was found that the required GPRS system was indeed present in these cells, although the exact location and mechanism is not known at this time. Vertebrate rhodopsin has a much lower light threshold due to the GPRS amplification and a much wider wavelength range when compared to microorganism rhodopsin. The kinetics of vertebrate rhodopsins are slower than the microorganism rhodopsins due to the necessary chemical cascades. The recycle times of the optogenetic vertebrate rhodopsin incorporated into ON bipolar cells are high because bipolar cells do not contain the proteins and processes found in retinal photoreceptors, which rapidly terminate the light response of the GPRS cascade.
Knockout blind mice that have had either the invertebrate or vertebrate rhodopsins incorporated into the ON bipolar cells demonstrate both visual evoked potentials responses and positive visual behaviors. Human trials with microorganism-derived channel rhodopsin 2 (ChR2) are currently under way.
Future improvements in the system will be achieved when differential sensitivity to different wavelengths can restore some color discrimination. This could be achieved by the optogenetic placement of more than one rhodopsin system, each of which has a different wavelength sensitivity. Improvements in vision will occur when specific subtissue targets can be achieved, such as finding gene promoters that will allow for hyperpolarization of the bipolar cell dendritic tips and depolarization of the cell soma. Photostimulation of OFF bipolar cells will also add important visual information.
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